Skip to content
biosimilar development

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Hadlima
    • Herzuma
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Renflexis
    • Retacrit
    • Ruxience
    • Trazimera
    • Truxima
    • Udenyca
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The Biosimilars Market Report
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

Recent Posts

  • An Oncologist’s Concern About the Biosimilar Use in Real-World Patients With Cancer December 31, 2020
  • Amgen Receives FDA Approval for Rituximab Biosimilar Riabni December 22, 2020
  • The Limitations of Direct-to-Consumer Advertising for Biosimilars December 21, 2020
  • Biosimilar Company Updates: Tanvex, Bio-Thera, and Coherus December 14, 2020
  • Supreme Court Deliberations on the ACA: Impact on Employers’ Biosimilar Strategy December 4, 2020
  • Many More Questions Than Answers in Medicare’s Most-Favored Nation Interim Final Rule December 1, 2020
  • The Medicare Part D Rebate Rule and Biosimilars November 24, 2020
  • Archigen Closes Its Doors After Failing to Introduce Rituximab Biosimilar November 20, 2020
  • Wraparound Services: Biosimilar Makers Must Be Sure to Get Them Right November 19, 2020
  • Samsung Bioepis’ Ranibizumab Biosimilar Application Filed With FDA November 18, 2020

Recent Comments

Paul C on An Oncologist’s Concern About…
Taking the Long View… on Merck to Spin Off Company That…
Taking the Long View… on The Baby, Biosimilars, and the…
An Oncologist’s Conc… on Analyzing FDA Chief Gottlieb’s…
Biosimilar Company U… on Updates on Some Lesser-Known M…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • The Evolution of the Biosimilars Market
  • Biosimilar Approval Status
  • Who Are the Key Lucentis Biosimilar Players to Watch?
  • Home
  • Apotex/Apobiologix: Success in Canada, but Are They Shelving Biosimilars in the US?
  • Ruxience
  • Phase 3 Studies in Biosimilars: Do They Tell Us Enough to Be Useful?
  • Ogivri
  • Zirabev
  • Fresenius Kabi and Celltrion Get Good News
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2013-2021 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.